DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Midostaurin |
DMI6E0R
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[7] |
Oliceridine |
DM6MDCF
|
Moderate |
Altered metabolism of Canakinumab due to Oliceridine alters the formation of CYP450 enzymes. |
Acute pain [MG31]
|
[8] |
Siltuximab |
DMGEATB
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Siltuximab. |
Anemia [3A00-3A9Z]
|
[7] |
Dupilumab |
DMOAD2Y
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Dupilumab. |
Atopic eczema [EA80]
|
[7] |
Eribulin |
DM1DX4Q
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[7] |
Talazoparib |
DM1KS78
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Talazoparib. |
Breast cancer [2C60-2C6Y]
|
[7] |
LY2835219 |
DM93VBZ
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and LY2835219. |
Breast cancer [2C60-2C6Y]
|
[7] |
Pralatrexate |
DMAO80I
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Pralatrexate. |
Breast cancer [2C60-2C6Y]
|
[7] |
Palbociclib |
DMD7L94
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Palbociclib. |
Breast cancer [2C60-2C6Y]
|
[7] |
Cabazitaxel |
DMPAZHC
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Cabazitaxel. |
Breast cancer [2C60-2C6Y]
|
[7] |
Bosutinib |
DMTI8YE
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Bosutinib. |
Breast cancer [2C60-2C6Y]
|
[7] |
Aflibercept |
DMT3D5I
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Aflibercept. |
Colorectal cancer [2B91]
|
[7] |
Levonorgestrel |
DM1DP7T
|
Moderate |
Altered metabolism of Canakinumab due to Levonorgestrel alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[8] |
Rivaroxaban |
DMQMBZ1
|
Moderate |
Altered metabolism of Canakinumab due to Rivaroxaban alters the formation of CYP450 enzymes. |
Deep vein thrombosis [BD71]
|
[8] |
Polatuzumab vedotin |
DMF6Y0L
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Polatuzumab vedotin. |
Diffuse large B-cell lymphoma [2A81]
|
[7] |
Axicabtagene ciloleucel |
DMYHN59
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Axicabtagene ciloleucel. |
Diffuse large B-cell lymphoma [2A81]
|
[7] |
Oestradiol valerate and dienogest |
DMZK0FQ
|
Moderate |
Altered metabolism of Canakinumab due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes. |
Endometriosis [GA10]
|
[9] |
Bay 80-6946 |
DMLOS5R
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Bay 80-6946. |
Follicular lymphoma [2A80]
|
[7] |
Avapritinib |
DMK2GZX
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Avapritinib. |
Gastrointestinal stromal tumour [2B5B]
|
[7] |
177Lu-DOTATATE |
DMT8GVU
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and 177Lu-DOTATATE. |
Hepatitis virus infection [1E50-1E51]
|
[7] |
Brentuximab vedotin |
DMWLC57
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[7] |
Teriflunomide |
DMQ2FKJ
|
Major |
Additive immunosuppressive effects by the combination of Canakinumab and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[10] |
Levamlodipine |
DM92S6N
|
Moderate |
Altered metabolism of Canakinumab due to Levamlodipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[8] |
Denosumab |
DMNI0KO
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Denosumab. |
Low bone mass disorder [FB83]
|
[11] |
Brigatinib |
DM7W94S
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Brigatinib. |
Lung cancer [2C25]
|
[7] |
Lurbinectedin |
DMEFRTZ
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Lurbinectedin. |
Lung cancer [2C25]
|
[8] |
Osimertinib |
DMRJLAT
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Osimertinib. |
Lung cancer [2C25]
|
[7] |
Belimumab |
DM3OBQF
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Belimumab. |
Lupus erythematosus [4A40]
|
[7] |
Ofatumumab |
DM295PR
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Ofatumumab. |
Mature B-cell leukaemia [2A82]
|
[7] |
Obinutuzumab |
DM3BVAE
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Obinutuzumab. |
Mature B-cell leukaemia [2A82]
|
[7] |
Idelalisib |
DM602WT
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Idelalisib. |
Mature B-cell leukaemia [2A82]
|
[7] |
GDC-0199 |
DMH0QKA
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and GDC-0199. |
Mature B-cell leukaemia [2A82]
|
[7] |
IPI-145 |
DMWA24P
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and IPI-145. |
Mature B-cell leukaemia [2A82]
|
[7] |
Acalabrutinib |
DM7GCVW
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Acalabrutinib. |
Mature B-cell lymphoma [2A85]
|
[7] |
Blinatumomab |
DMGECIJ
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Blinatumomab. |
Mature B-cell lymphoma [2A85]
|
[7] |
Ibrutinib |
DMHZCPO
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Ibrutinib. |
Mature B-cell lymphoma [2A85]
|
[7] |
Tisagenlecleucel |
DMM9BJD
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Tisagenlecleucel. |
Mature B-cell lymphoma [2A85]
|
[7] |
Ponatinib |
DMYGJQO
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[7] |
Carfilzomib |
DM48K0X
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Carfilzomib. |
Multiple myeloma [2A83]
|
[7] |
Panobinostat |
DM58WKG
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Panobinostat. |
Multiple myeloma [2A83]
|
[7] |
Selinexor |
DMBD4K3
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Selinexor. |
Multiple myeloma [2A83]
|
[7] |
Belantamab mafodotin |
DMBT3AI
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Belantamab mafodotin. |
Multiple myeloma [2A83]
|
[7] |
Elotuzumab |
DMEYHG9
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Elotuzumab. |
Multiple myeloma [2A83]
|
[7] |
Daratumumab |
DMKCIUZ
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Daratumumab. |
Multiple myeloma [2A83]
|
[7] |
Tecfidera |
DM2OVDT
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Tecfidera. |
Multiple sclerosis [8A40]
|
[7] |
Siponimod |
DM2R86O
|
Major |
Additive immunosuppressive effects by the combination of Canakinumab and Siponimod. |
Multiple sclerosis [8A40]
|
[6] |
Fingolimod |
DM5JVAN
|
Major |
Additive immunosuppressive effects by the combination of Canakinumab and Fingolimod. |
Multiple sclerosis [8A40]
|
[12] |
Ocrelizumab |
DMEZ2KH
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Ocrelizumab. |
Multiple sclerosis [8A40]
|
[7] |
Ozanimod |
DMT6AM2
|
Major |
Additive immunosuppressive effects by the combination of Canakinumab and Ozanimod. |
Multiple sclerosis [8A40]
|
[8] |
Deflazacort |
DMV0RNS
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Deflazacort. |
Muscular dystrophy [8C70]
|
[7] |
Romidepsin |
DMT5GNL
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Romidepsin. |
Mycosis fungoides [2B01]
|
[7] |
Ruxolitinib |
DM7Q98D
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Ruxolitinib. |
Myeloproliferative neoplasm [2A20]
|
[7] |
Inebilizumab |
DMI0RHA
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Inebilizumab. |
Nervous system paraneoplastic/autoimmune disorder [8E4A]
|
[7] |
Atezolizumab |
DMMF8U0
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Atezolizumab. |
Non-small cell lung cancer [2C25]
|
[7] |
Olaparib |
DM8QB1D
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Olaparib. |
Ovarian cancer [2C73]
|
[7] |
Rucaparib |
DM9PVX8
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Rucaparib. |
Ovarian cancer [2C73]
|
[7] |
MK-4827 |
DMLYGH4
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and MK-4827. |
Ovarian cancer [2C73]
|
[7] |
Brodalumab |
DMASDQ6
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Brodalumab. |
Psoriasis [EA90]
|
[7] |
Tildrakizumab |
DMLW9HG
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Tildrakizumab. |
Psoriasis [EA90]
|
[7] |
Risankizumab |
DMM32GT
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Risankizumab. |
Psoriasis [EA90]
|
[7] |
Ixekizumab |
DMXW92T
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Ixekizumab. |
Psoriasis [EA90]
|
[7] |
Temsirolimus |
DMS104F
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Temsirolimus. |
Renal cell carcinoma [2C90]
|
[8] |
Anthrax vaccine |
DM9GSWY
|
Moderate |
Antagonize the effect of Canakinumab when combined with Anthrax vaccine. |
Sepsis [1G40-1G41]
|
[13] |
Mogamulizumab |
DMISH0Z
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Mogamulizumab. |
Sezary syndrome [2B02]
|
[7] |
LEE011 |
DMMX75K
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and LEE011. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Pomalidomide |
DMTGBAX
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Pomalidomide. |
Systemic sclerosis [4A42]
|
[7] |
Plicamycin |
DM7C8YV
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Plicamycin. |
Testicular cancer [2C80]
|
[7] |
Apixaban |
DM89JLN
|
Moderate |
Altered metabolism of Canakinumab due to Apixaban alters the formation of CYP450 enzymes. |
Thrombosis [DB61-GB90]
|
[8] |
Belatacept |
DMXLYQF
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Belatacept. |
Transplant rejection [NE84]
|
[7] |
Durvalumab |
DM4PVDY
|
Moderate |
Additive immunosuppressive effects by the combination of Canakinumab and Durvalumab. |
Ureteral cancer [2C92]
|
[7] |
----------- |
|
|
|
|
|